Ohio State University Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ohio State University Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count).
Ohio State University Comprehensive Cancer Center: 341 sponsored US clinical trials, 77 recruiting.
Ohio State University Comprehensive Cancer Center sponsors 341 registered US clinical trials on ClinicalTrials.gov, 77 of them currently recruiting, and 206 completed. 5 of these trials are in Phase 3-4 (later-stage) and 116 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anatomic Stage II Breast Cancer AJCC v8, with 10 trials.
Top-decile sponsor footprint
Ohio State University Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#105 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
206 of 217 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
341 total, page 5 of 7
Examination of Low Wattage and High Wattage E-Cigarettes
NCT03113136
Sarcoma Treatment Guide in Improving Self-Monitoring in Patients With Sarcoma Receiving Chemotherapy
NCT03258892
Nutrition and Exercise Trial: Improving Diet and Physical Activity Patterns in Overweight Cancer Survivors
NCT03489213
Educational Intervention - Improving Knowledge and Screening Rates for Colorectal Cancer
NCT03287453
Daratumumab in Treating Patients With Multiple Myeloma
NCT02944565
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
NCT02760030
Rural Interventions for Screening Effectiveness
NCT02795104
mHealth Intervention in Increasing HPV Vaccinations in College Students
NCT02960100
Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer
NCT02831582
Expiratory Muscle Strength Training in Improving Bulbar Function and Quality of Life in Patients With Head and Neck Cancer
NCT03175289
Exercise Prehab in Older Adults With Hematologic Malignancies
NCT02791737
Computerized Cognitive Behavior Therapy in Treating Depression in Patients With Cancer
NCT02837887
Mobile Health Intervention in Increasing HPV Vaccine Coverage Among Young Adult Gay and Bisexual Men
NCT02835755
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
NCT02569320
Quality of Life and Supportive Care Preferences Following Radiation Therapy in Prostate Cancer Survivors
NCT02704377
Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
NCT02186470
Checklist Tool in Engaging Patients in the Discharge Planning Process
NCT02942524
Effects of Electronic Cigarette Use on the Lungs
NCT02596685
Effect of Black Raspberry Phytochemicals on Oral Microbiome in Current Smokers and Non-smokers
NCT02439255
HPV Self-Test Intervention in Ohio Appalachia
NCT02460237
Sensorimotor Rehabilitation Program in Improving Quality of Life in Patients With Early Stage Breast Cancer
NCT03568526
Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT02507765
Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer
NCT02203552
Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery
NCT02262325
Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery
NCT02144649
Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors
NCT03039140
Taste Acceptability of Tomato-Soy-Arugula Seed Beverages in Men With Prostate Cancer
NCT02927899
Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer
NCT02400060
Aromatherapy and Essential Oils in Improving Insomnia and Other Symptoms in Patients With Newly Diagnosed Acute Leukemia Undergoing Chemotherapy
NCT02445378
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
NCT02107755
Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy
NCT02193568
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT02035527
Comprehensive Frailty Assessment
NCT02033928
Harvesting Health Program in Improving Diet and Physical Activity Level in Cancer Survivors
NCT02268188
iPad Use in Reducing Anxiety and Depression in Patients Undergoing Bone Marrow Transplant
NCT02378012
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02077959
Biomarker Identification for Bladder Cancer Patients
NCT02053662
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
NCT02005289
Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer
NCT02415387
Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer
NCT02125019
Stress Management for Cancer Patients: How Well Does it Work? (C2H-D)
NCT02070250
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
NCT01987726
Adherence to Colon Cancer Screening (ACCS)
NCT02112747
Gentle Yoga and Dietary Counseling in Improving Physical Function and Quality of Life in Stage I-II Endometrial Cancer Survivors
NCT02465541
Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
NCT01975363
Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
NCT02050906
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01812005
Lymph Node Mapping in Patients With Endometrial Cancer
NCT01818739
Ohio Colorectal Cancer Prevention Initiative
NCT01850654
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
NCT01740648
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 59 |
| Phase 3 | 1 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the Ohio State University Comprehensive Cancer Center pipeline
77 recruiting of 341 indexed (23% open); 206 completed (60%).
Phase mix: 5 late (III/IV) vs 116 early (I/II) (early-phase heavy).
Top condition: Anatomic Stage II Breast Cancer AJCC v8 (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ohio State University Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 341 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Ohio State University Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 341 trials (± recruiting share)
- Children's Oncology Group · 342 trials · 10% recruiting
- National Institute of Mental Health (NIMH) · 343 trials · 12% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
Sponsors near 23% open enrollment (± trial volume)
- University of Delaware · 23% recruiting · 106 trials
- University of Virginia · 22% recruiting · 449 trials
- University of Kansas Medical Center · 23% recruiting · 408 trials
- University of Oklahoma · 22% recruiting · 358 trials
Related
What to do with this Ohio State University Comprehensive Cancer Center page
341 registered trials is a research-attention snapshot, not an endorsement of Ohio State University Comprehensive Cancer Center or any single study.
- 77 of Ohio State University Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Anatomic Stage II Breast Cancer AJCC v8 is the condition Ohio State University Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anatomic Stage II Breast Cancer AJCC v8 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ohio State University Comprehensive Cancer Center pipeline card: 341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.